First Trust Nasdaq Pharmaceuticals ETF

Most Recent

  • uploads///Vaccines
    Company & Industry Overviews

    Pfizer’s Vaccines: A Look at Their Market Performance

    In the first nine months of this year, Pfizer’s (PFE) vaccines sales grew ~7% YoY (year-over-year) to $4.7 billion from $4.4 billion.

    By Daniel Collins
  • uploads///world _
    Earnings Report

    Allergan’s Q3 2018 Earnings: Analysts’ Estimates

    Allergan (AGN) is set to release its Q3 2018 earnings on October 30. Analysts estimate EPS of $4.03 on revenues of $3.88 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer: Analysts Expect Revenue Growth in Q3

    Analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to the third quarter of 2017.

    By Mike Benson
  • uploads///headache _
    Company & Industry Overviews

    Analyzing Pfizer’s Stock Performance in October

    Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Eli Lilly’s Stock Performance and Estimates for Q3 2018

    Sixteen analysts currently track Eli Lilly (LLY) stock. Two analysts recommend a “strong buy,” six analysts recommend a “buy,” and eight analysts recommend a “hold.”

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Revenue and EPS Growth Rate

    Pfizer (PFE) reported EPS of $0.74 on revenue of ~$13.5 billion in the second quarter, surpassing Wall Street analysts’ consensus estimate.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s First Medical Aesthetics Innovation Center in China

    Allergan’s total investment in the Medical Aesthetics and Innovation Center is ~$14.7 million.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Does Sage Therapeutics’ Product Portfolio Look in September?

    Sage Therapeutics’ (SAGE) product portfolio includes products under development for the treatment of various rare and life-threatening central nervous system disorders.

    By Mike Benson
  • uploads///Chart  Valuation Comparison
    Company & Industry Overviews

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Eli Lilly’s New Products in Q2 2018

    Eli Lilly and Company’s (LLY) new products portfolio includes new products that have been launched since 2014.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s International Business Segment in Q2 2018

    Allergan’s International Business segment reported revenue of $949 million in the second quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Sage Therapeutics’ NMDA Receptor–Based Products

    Sage Therapeutics developed SAGE-718, which targets the NMDA Receptor.

    By Mike Benson
  • uploads///laboratory _
    Company & Industry Overviews

    SAGE Therapeutics’ Stock Performance and Estimates in June

    SAGE Therapeutics’ stock price has risen nearly 111.5% in the last 12 months.

    By Mike Benson
  • uploads///people _
    Company & Industry Overviews

    Sage’s Brexanolone IV: FDA Grants Priority Review

    On May 30, Sage Therapeutics announced that the FDA accepted the new drug application for Brexanolone IV.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Merck’s Animal Health Segment Did in 1Q18

    In 1Q18, Merck’s (MRK) Animal Health segment, which includes drugs and vaccines for animals, saw its revenue grow 13% YoY (year-over-year) to ~$1.1 billion from $939 million.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    How Analysts View Allergan after Its 1Q18 Earnings

    Allergan (AGN) surpassed Wall Street analysts’ estimates, reporting earnings per share of $3.74 on revenues of $3.7 billion during 1Q18.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Wall Street Recommendations for Merck & Co. before Earnings

    Wall Street analysts expect Merck & Co.’s (MRK) top line to increase 7.1% to $10.1 billion for 1Q18, compared to revenues of $9.4 billion for 1Q17.

    By Mike Benson
  • uploads///pill _
    Healthcare

    These Pharma Stocks Offer the Most Upside Potential

    In 2018, stock markets, especially in the pharmaceutical sector, have seen heightened volatility.

    By Kenneth Smith
  • uploads///pill _
    Earnings Report

    What Do Analysts Predict for Bristol-Myers Squibb in 1Q18?

    Analysts estimate Bristol-Myers Squibb will post EPS of $0.85 and revenues of $5.2 billion for 1Q18.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18

    Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.

    By Mike Benson
  • uploads///Chart  BMY
    Company & Industry Overviews

    How Bristol-Myers Squibb Stock Performed in 1Q18

    Bristol-Myers Squibb stock has fallen ~1.6% in 1Q18, and its stock has fallen ~0.6% YTD (year-to-date) as of April 6, 2018.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Eli Lilly’s Segment-by-Segment Performance in 4Q17

    Eli Lilly and Company’s (LLY) products are classified into two business segments: Human Pharmaceuticals and Animal Health.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Wall Street Analysts’ Recommendations for JNJ in January 2018

    Wall Street analysts expect Johnson & Johnson to generate EPS of $2.01 on revenues of ~$19.4 billion in 1Q18 for 9.2% growth in revenues compared to 1Q17.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Pfizer’s 4Q17 Estimates: Products with Lower Sales

    In Pfizer’s (PFE) portfolio, a few of the products reported a lower sales trend due to competition from other products in the markets.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Wall Street Recommendations for Mylan in January 2018

    As we discussed earlier in this series, Mylan (MYL) reported revenues of $2.98 billion in 3Q17, a 2.3% decline in revenues compared to $3.06 billion in 3Q16.

    By Mike Benson
  • uploads///Chart  Recommendations
    Company & Industry Overviews

    Analysts’ Recommendations for Pfizer 4Q17

    Analysts’ estimates Between 4Q16 and 4Q17, Wall Street analysts expect Pfizer’s (PFE) revenue to rise ~0.8% to $13.72 billion from $13.63 billion. However, analysts expect it to fall ~0.5% to $52.6 billion in 2017 from $52.8 billion in 2016. They expect Pfizer to see EPS (earnings per share) of $0.56 in 4Q17 and $2.59 in 2017. Analysts’ ratings The above chart shows analysts’ recommendations […]

    By Mike Benson
  • uploads///Chart  New
    Company & Industry Overviews

    Eli Lilly’s New Products Portfolio in 3Q17

    Eli Lilly and Co.’s (LLY) product portfolio includes Basaglar, Jardiance, Cyramza, Lartruvo, Taltz, Olumiant, and Trulicity.

    By Mike Benson
  • uploads///Opsumit
    Company & Industry Overviews

    How JNJ’s Pulmonary Hypertension Portfolio Performed in 3Q17

    In 3Q17, in the US and outside the US (international markets), JNJ’s pulmonary hypertension portfolio generated revenues of $357 million and $283 million, respectively.

    By Daniel Collins
  • uploads///lipitor
    Company & Industry Overviews

    How Pfizer’s Established Products Have Performed

    In 3Q17, Pfizer’s (PFE) Lipitor reported revenues of $491 million, a ~16% increase on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Chart  EPS
    Healthcare

    Bristol-Myers Squibb’s Valuations after Its 3Q17 Earnings

    Of the 22 analysts covering Bristol-Myers Squibb, nine analysts recommend a “buy,” 11 analysts recommend a “hold,” and two analysts recommend a “sell.”

    By Mike Benson
  • uploads///Chart  AR
    Earnings Report

    Analysts’ Ratings and Recommendations for Johnson & Johnson

    JNJ’s stock price has increased nearly 16.2% in the last 12 months and nearly 18.6% year-to-date.

    By Mike Benson
  • uploads///Chart  Orencia
    Company & Industry Overviews

    Bristol-Myers Squibb’s Immunoscience Products

    Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Johnson & Johnson’s Medical Devices Segment Performed

    Johnson & Johnson’s (JNJ) medical devices segment includes cardiovascular care, diabetes care, orthopedics, surgery, and vision care products.

    By Mike Benson
  • uploads///Chart  NGC
    Company & Industry Overviews

    These Pfizer’s Products Are Now Losing Market Share

    Pfizer’s (PFE) Essential Health segment reported a fall in overall revenues in 2Q17, driven by the loss of exclusivity of Celebrex and Zyvox.

    By Mike Benson
  • uploads///Chart  GABA
    Company & Industry Overviews

    What Are Sage Therapeutics’ GABA Receptor Products?

    The products under development for the treatment of life-threatening central nervous system (or CNS) disorders in Sage Therapeutics’ (SAGE) portfolio are either based on GABA or NMDA receptor systems.

    By Mike Benson
  • uploads///Chart  AHR
    Company & Industry Overviews

    Behind Merck’s Animal Health Segment Performance in 2Q17

    Merck’s (MRK) Animal Health segment includes drugs and vaccines for animals and has operations spread across more than 140 countries worldwide.

    By Mike Benson
  • uploads///Chart  Segment
    Company & Industry Overviews

    Performance of Eli Lilly’s Business Segments in 2Q17

    The Human Pharmaceuticals segment reported revenues of ~$5.0 billion during 2Q17, representing 10.9% growth compared to its 2Q16 revenues.

    By Mike Benson
  • uploads///Biosimilars
    Company & Industry Overviews

    What to Expect from Pfizer’s Biosimilars Business

    In 2Q17, Pfizer’s Inflectra/Remsima reported revenues of ~$94 million compared to $45 million in 2Q16.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Major Developments for Johnson & Johnson in 2Q17

    Major developments All of Johnson & Johnson’s (JNJ) segments performed positively in 2Q17. In this part. we’ll look at some developments that occurred during the quarter. Pharmaceuticals On August 21, 2017, Johnson & Johnson presented new data for its COMPASS study, a phase III study evaluating Xarelto as a treatment for coronary and peripheral artery disease. […]

    By Mike Benson
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    Pfizer’s Valuation after 2Q17 Earnings

    Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. It reported a 2% decline in revenues, to $12.89 billion in 2Q17 from $13.15 billion in 2Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Johnson & Johnson’s Revenue Trend in 3Q16

    In 3Q16, Johnson & Johnson’s (JNJ) top line rose 4.2% to ~$17.8 billion, driven by 4.3% operational growth in revenues.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Bristol-Myers Squibb’s 3Q16 Estimates: Oncology Segment

    Opdivo is a human PD-1 blocking antibody used in lung cancer and melanoma treatments. Opdivo is part of BMY’s alliance with Ono Pharmaceutical.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Good News: Johnson & Johnson’s 3Q16 Revenues Expected to Rise

    Analysts expect Johnson & Johnson’s (JNJ) 3Q16 revenues to rise 3.7% to $17.7 billion. The expectation comes on the back of an increase in sales of its blockbuster drugs.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.